Megan Herr on Muck Rack

Megan Herr

Verified
Baton Rouge
As seen in: Decision Health, Nature, JAMA (The Journal of the American Medical Association), Corporate Counsel, Law360, JD Supra, Security Magazine, Mondaq, Journal of The American Academy of Dermatology (JAAD), Northern Virginia Magazine, Waynesboro Record Herald and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Megan

Contact Megan, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium

|
By Andrew J. Portuguese, James Davis, Shahzad Raza, Omar Castaneda Puglianini, Ciara L Freeman, Melissa Alsina, Corbin Wright, Brandon Blue, Rachid Baz, Kenneth H Shain, Utkarsh Goel, Jack Khouri, Faiz Anwer, Hossam Ali, Oren Pasvolsky, Mahmoud R. Gaballa, Damian Mikulski, Lindsay Fogel, Eli Zolotov, Aishwarya Sannareddy, Aimaz Afrough, Larry D. Jr, Kelley Julian, Danai Dima, Rahul Banerjee, Emily Liang, Raffaella Cassano, Megan Herr , Hamza Hassan, Leyla O. Shune, Jeries Kort, Shonali Midha, Omar Nadeem, Surbhi Sidana, Yi Lin, Frederick Locke, Doris Hansen, Douglas Sborov, Noa Biran, Ariel Grajales-Cruz, Hector Garcia-Pleitez
| Nature
Abstract Elranatamab, a BCMA-CD3 bispecific antibody, has demonstrated robust activity in relapsed/refractory multiple myeloma (RRMM), but real-world outcomes remain poorly defined. We conducted a multicenter retrospective study of 130 patients treated with commercial elranatamab across nine U.S. academic centers. The cohort was heavily pretreated (91% triple-class refractory, 49% penta-refractory), with 49% previously exposed to BCMA-targeted therapies.
Open in Who Shared Issue with article?

Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)—real world experience from the US multiple myeloma immunotherapy consortium

|
By CINDY varga, Myra Robinson, James Davis, Hamza Hashmi, Thomas Martin, Anupama Kumar, Douglas Sborov, Charlotte Wagner, Doris Hansen, Omar Castaneda Puglianini, Leyla O. Shune, Aimaz Afrough, Larry D. Jr, Binod Dhakal, Megan Herr , Shambavi Richard, Alex Lieberman-Cribbin, Daniel W. Sherbenou, Peter Forsberg, Sneha Purvey, Jack Khouri, Yi Lin, Surbhi Sidana, Shonali Midha, Christopher J. Ferreri, Evgeunia Bhurtel, Mehmet Kocoglu
| Nature
Abstract Prolonged cytopenias are a well-recognized complication following CAR-T therapy. Autologous SCB offers a potential strategy to promote fast hematologic recovery. We conducted a retrospective multi-institutional comparing outcomes of SCB versus supportive care alone in patients with prolonged cytopenias after CAR-T infusion. Patients were included if they received SCB within 1 year following commercial CAR-T between 6/2021 and 3/2024.
Open in Who Shared Issue with article?

The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience | Blood Cancer Journal

|
By Aimaz Afrough, Utkarsh Goel, Oren Pasvolsky, Mariola Vazquez-Martinez, Christopher J. Ferreri, Rahul Banerjee, Jack Khouri, James Davis, Mahmoud R. Gaballa, Masooma Rana, Kelley Julian, Faiz Anwer, Sandra Susanibar-Adaniya, Andrew J. Portuguese, Daniel Schrum, Gurbakhash Kaur, Joseph McGuirk, Megan Herr , Omar Castañeda, Shahzad Raza, Yi Lin, Shebli Atrash, Douglas Sborov, Peter M Voorhees, Shambavi Richard, Alfred Garfall, Surbhi Sidana, Doris Hansen, Alex Lieberman-Cribbin
| Nature
Abstract Teclistamab, a bispecific antibody targeting B-cell maturation antigen (BCMA), is effective in relapsed or refractory multiple myeloma (RRMM), but its impact on patients with soft tissue plasmacytomas is unclear. We studied 385 RRMM patients treated with teclistamab at 13 U.S. centers through September 2023, with follow-up to April 2024.
Open in Who Shared Issue with article?
See all 562 articles

Actions

Share this page

Get in touch with Megan

Contact Megan, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified